Aducanumab-avwa (Aduhelm™)

Aducanumab‑avwa (Aduhelm) is not recommended for approval or coverage due to insufficient evidence of clinical benefit and demonstrated safety concerns in trials, so coverage is not supported without additional clinical trial data. If requested, treatment must be for the FDA‑approved indication (Alzheimer's) and initiated in the mild cognitive impairment or mild dementia stages with documentation meeting the specific coverage and safety criteria.

"When requesting Aduhelm (aducanumab-avwa), the individual requiring treatment must be diagnosed with a FDA-approved indication and meet the specific coverage guidelines and applicable safety criter..."

Sign up to see full coverage criteria, indications, and limitations.